EMN29

Title

A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Overview / Summary

Study details

Participating countries include:

Germany (7 sites)

Italy (12 sites)

Greece (5 sites)

France (7 sites)

Netherland (6 sites)

Spain (10 sites)

USA (30 sites)

Patient eligibility criteria

Pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an IMiD, PI and an anti-CD38 mAb.

Publications